Immunocore Holdings plc — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Immunocore announced full enrollment of 540 patients in TEBE-AM, a Phase 3 registrational trial testing KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab versus Investigator's Choice in HLA-A*02:01-positive patients with previously treated advanced melanoma. The primary endpoint is overall survival; topline data expected end of 2026. The trial addresses an estimated 4,000-patient addressable market in the US and Europe for the post-PD1 setting.
Why this rating
Enrollment completion is a key de-risking milestone for lead late-stage program. Material for $1.5B biotech: successful Phase 3 enrollment removes execution risk, supports potential accelerated approval path, de-risks revenue runway. Results still pending.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.67% over 4 hrs, n=66). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $32.90 | +10 min · unknown $32.77 ▼ 0.40% | +30 min · unknown $32.77 ▼ 0.41% | +1 hr · unknown $32.45 ▼ 1.37% | +4 hrs · unknown $32.74 ▼ 0.47% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.